We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




GE Healthcare and Roche Partner to Develop Digital Diagnostics Platform

By LabMedica International staff writers
Posted on 16 Jan 2018
Print article
GE Healthcare (Chicago, IL, USA) and Roche (Basel, Switzerland) have entered into a strategic, long-term partnership to jointly develop and co-market digital clinical decision support solutions. Initially, the partnership will focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.

GE Healthcare is a leading provider of medical imaging equipment, harnessing data and analytics across hardware, software and biotech. Roche is a pioneer in pharmaceuticals and diagnostics, and is the world’s largest biotech company, offering differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. The company is also a leader in the fields of in vitro diagnostics and tissue-based cancer diagnostics, and is a frontrunner in diabetes management.

Together, the companies will focus on developing the first digital platform in the industry, using advanced analytics to provide workflow solutions and apps that support clinical decisions. This will enable seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes. This will also provide comprehensive decision support to clinicians for offering the right treatment and quality of care for their patients.

For instance, oncology care teams with multiple specialists will be able to access a comprehensive data dashboard to review, collaborate and align on treatment decisions for cancer patients at each stage of their disease. Similarly, in the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, genomic and sequencing data to help physicians identify, or even predict severe complications before they arise.

“This unique partnership will deliver innovative solutions and insights in clinical decision-making,” said Roland Diggelmann, CEO Roche Diagnostics. “Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”

“This is the first time that two major players in healthcare have combined digital, in-vivo and in-vitro diagnostics to this degree,” said Kieran Murphy, President and CEO of GE Healthcare. “We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.